---
document_datetime: 2026-01-16 16:27:24
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/sugammadex-adroiq-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: sugammadex-adroiq-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 10.0816373
conversion_datetime: 2026-01-17 23:15:37.926835
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.68.0
  docling-core: 2.59.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Sugammadex Adroiq

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                           | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|---------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IA /  | A. ADMINISTRATIVE CHANGES - A.7 | 16/01/2026                          |                                             | Annex II and                     |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                                          | Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted                                                                                                                                                                                                                                                                                                                               |            |     | PL                     | EMA/VR/0000322606   |
|------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------|---------------------|
| Variation type IA_IN / EMA/VR/0000297355 | A. ADMINISTRATIVE CHANGES - A.1 Change in the name and/or address of the marketing authorisation holder - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 23/09/2025 |     | SmPC, Labelling and PL |                     |
| Variation type IB / EMA/VR/0000282615    | This was an application for a group of variations. B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.z Other variation - Accepted B.I.d.1.a Re-test period/storage period - B.I.d.1.a.4 Extension or introduction of a re- test period/storage period supported by real time data - Accepted B.I.a.2 Changes in the manufacturing | 04/08/2025 | N/A |                        |                     |

<div style=\"page-break-after: always\"></div>

| Minor change in the manufacturing process         |
|---------------------------------------------------|
| of the active substance - Accepted                |
| B.I.a.1 Change in the manufacturer of a           |
| starting material/reagent/intermediate used       |
| in the manufacturing process of the active        |
| substance or change in the manufacturer           |
| (including where relevant quality control         |
| testing sites) of the active substance, where     |
| no Ph. Eur. Certificate of Suitability is part of |
| the approved dossier - B.I.a.1.z Other            |
| variation - Accepted                              |
| B.I.a.3 Change in batch size (including batch     |
| size ranges) of active substance or               |
| intermediate used in the manufacturing            |
| process of the active substance - B.I.a.3.a       |
| Up to 10-fold increase compared to the            |
| originally approved batch size - Accepted         |
| A. ADMINISTRATIVE CHANGES - A.4 Change            |
| in the name and/or address of: a                  |
| manufacturer (including where relevant            |
| quality control testing sites); or an ASMF        |
| holder; or a supplier of the active substance,    |
| used in the manufacture of the active             |
| substance (where specified in the technical       |
| Suitability is part of the approved dossier;      |
| or                                                |
| specified in the technical dossier) - Accepted    |

<div style=\"page-break-after: always\"></div>

| Variation type IB / EMA/VR/0000257364    | C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2.a - To update section 4.8 of the SmPC for Hypersensitivity following assessment of the same change for the reference product Bridion 100 mg/mL solution for injection.   | 31/03/2025   |     | SmPC   |
|------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-----|--------|
| Variation type IA_IN / EMA/VR/0000251824 | C.I.3 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of human medicinal products intended to implement the outcome of a procedure concerning PSUR or PASS, or the outcome of the assessment done by the competent authority under Articles 45 or 46 of Regulation 1901/2006 - C.I.3.a Implementation of wording agreed by the competent authority - Refused                                                                                                                      | 27/02/2025   | N/A |        |